Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The discovery of small molecules targeted to specific oncogenic pathways has revolutionized anti-cancer therapy. However, such therapy often fails due to the evolution of acquired resistance. One long-standing question in clinical cancer research is the identification of optimum therapeutic administration strategies so that the risk of resistance is minimized. In this paper, we investigate optimal drug dosing schedules to prevent, or at least delay, the emergence of resistance. We design and analyze a stochastic mathematical model describing the evolutionary dynamics of a tumor cell population during therapy. We consider drug resistance emerging due to a single (epi)genetic alteration and calculate the probability of resistance arising during specific dosing strategies. We then optimize treatment protocols such that the risk of resistance is minimal while considering drug toxicity and side effects as constraints. Our methodology can be used to identify optimum drug administration schedules to avoid resistance conferred by one (epi)genetic alteration for any cancer and treatment type.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“Similarly, the T790M point mutation in the epidermal growth factor receptor (EGFR) confers resistance to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib [5], which are used to treat non-small cell lung cancer.”
BackgroundClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“For example, treatment of chronic myeloid leukemia (CML) with the targeted agent imatinib fails due to acquired point mutations in the BCRABL kinase domain [3].”
BackgroundThe role of glutathione-S-transferase in anti-cancer drug resistance
Townsend, D. M., & Tew, K. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206940 · Cited by 1,353
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807
Cited by
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
The mathematics of cancer: integrating quantitative models
Altrock, P. M., Liu, L. L., & Michor, F. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4029 · Cited by 685
Self-citationSignaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 525
Self-citationEvolution of acquired resistance to anti-cancer therapy
Foo, J., & Michor, F. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.02.025 · Cited by 254
Self-citation
Metadata
- Authors
- Foo, J., & Michor, F.
- Venue
- PLoS Computational Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-11-06
- Volume
- 5
- Issue
- 11
- Pages
- e1000557
- ISSN
- 1553-734X (ISSN-L)
- 1553-7358
- OpenAlex
- W2098560585
- Cited by
- 115
- References
- 5
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies. https://app.cochat.ai/papers/10.1371/journal.pcbi.1000557
- The paper
- Foo, J., & Michor, F. (2009). Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies. PLoS Computational Biology. https://doi.org/10.1371/journal.pcbi.1000557
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.